Benzylthiouracil
Benzylthiouracil (BTU) is an antithyroid preparation. It is a thioamide, closely related to propylthiouracil.
Adverse effects
Benzylthiouracil has been associated with severe adverse effects, notably vasculitis and subsequent ANCA-positive glomerulonephritis, as well as isolated reports of lung damage.[1][2][3][4]
References
- ↑ Tieulie N, Huong DL, Andreu M; et al. (2002). “[ANCA associated glomerulonephritis related to benzylthiouracil]”. Rev Med Interne (in French). 23 (10): 853–6. PMID 12428489.
- ↑ Kaaroud H, Khiari K, Ben Moussa F, Barbouch S, Boussema E, Ben Maïz H (2002). “[Vasculitis with renal and pulmonary involvement in a patient receiving benzylthiouracil for Graves disease]”. Rev Med Interne (in French). 23 (10): 857–61. PMID 12428490.
- ↑ Braham A, Houman MH, Rais L, Ben Gborbel I, Lamloum M, Miled M (2004). “[Benzylthiouracil induced ANCA-positive vasculitis]”. Presse médicale (in French). 33 (19 Pt 1): 1331–3. PMID 15615240.
- ↑ Thabet F, Sghiri R, Tabarki B, Ghedira I, Yacoub M, Essoussi AS (2006). “ANCA-associated diffuse alveolar hemorrhage due to benzylthiouracil”. Eur J Pediatr. 165 (7): 435–6. doi:10.1007/s00431-005-0053-4. PMID 16622664.
© 2026 MyEClinic – IFTM Institut für Telematik in der Medizin GmbH